Is BPC-157 Legal in North Carolina?

What Is BPC-157 and Why Does Its Legal Status Matter?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protein found in human gastric juice. Its amino acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Researchers have studied it primarily in rodent models for wound healing, tendon repair, and gut mucosal protection. Because it is neither a scheduled controlled substance nor an FDA-approved drug, it exists in a regulatory space that confuses patients, prescribers, and even some pharmacists.

The legal status matters for one practical reason: if you are in North Carolina and you want to use BPC-157, the pathway through which you obtain it determines whether that transaction is lawful.

What BPC-157 Is Not

BPC-157 is not a DEA-scheduled controlled substance under the Controlled Substances Act. The DEA maintains the schedules of controlled substances, and BPC-157 does not appear on any of them. It is also not a supplement with a legal dietary ingredient notification accepted by the FDA. Calling it a "supplement" on a label does not make it one under the law.

What BPC-157 Is

The FDA treats BPC-157 as a drug substance that requires an approved New Drug Application (NDA) or Abbreviated NDA before it can be marketed to humans. The FDA's authority over new drug substances is established under the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 321 et seq. No such application for BPC-157 has been approved or even filed in the United States as of the date of this article.

The FDA's Specific Position on BPC-157 in Compounding

This section is where the regulatory picture sharpens considerably for North Carolina patients.

The 503A Bulk Substances Nomination Process

Under Section 503A of the FD&C Act, licensed compounding pharmacies may prepare drugs from bulk drug substances if those substances appear on a list published by the FDA, are components of FDA-approved drugs, or have been used in compounding before 1997 with a history of safety. BPC-157 does not meet any of those three criteria cleanly.

The FDA convened its Pharmacy Compounding Advisory Committee (PCAC) to evaluate nominated bulk substances. BPC-157 was nominated for inclusion on the 503A list and was flagged by the FDA as presenting "a significant safety risk," placing it on the Category 2 list. The nominator later withdrew that nomination, and BPC-157 is no longer on the FDA's current Category 2 list. That withdrawal did not add BPC-157 to the 503A positive list, and it was never on that list. Compounding pharmacies operating under 503A rules still have no lawful basis to compound BPC-157 for injectable human use. In July 2026, the FDA's PCAC voted to recommend adding BPC-157 to the 503A bulks list (8 yes, 6 no, 1 abstain), but that vote is advisory only and BPC-157 remains off the list as of this writing.

The 503B Outsourcing Facility Framework

503B outsourcing facilities operate under stricter FDA oversight and may only use bulk drug substances that appear on an FDA-published list or that are components of FDA-approved drugs. BPC-157 does not appear on the 503B bulks list. This means 503B facilities also cannot lawfully compound BPC-157 for human use in the United States.

The practical result: the two main compounding pathways are both blocked at the federal level.

What BPC-157's Withdrawn Category 2 Flag Means in Plain Language

The FDA's Category 2 list flags substances that lack sufficient evidence of safety or clinical utility for use in compounding. BPC-157 was flagged there before its nomination was withdrawn in April 2026. The FDA's current Category 2 page no longer lists BPC-157. That withdrawal did not resolve the underlying evidence gap: no large randomized controlled trial in humans has established a safety and efficacy profile for BPC-157 at any dose, the published evidence base consists almost entirely of rodent and in-vitro studies, and BPC-157 still is not on the 503A bulks list.

North Carolina State Law: What Exists and What Does Not

North Carolina does not have a stand-alone statute that mentions BPC-157 by name. State law neither explicitly permits nor explicitly prohibits possession of BPC-157 for personal use. That silence is not the same as permission, because federal law still applies in North Carolina.

The NC Board of Pharmacy

The North Carolina Board of Pharmacy licenses and regulates pharmacies and pharmacists operating in the state. It adopts federal standards by reference, including USP chapter requirements and FDA guidance on compounding. A North Carolina-licensed 503A pharmacy is still bound by BPC-157's continued absence from the 503A bulks list, notwithstanding the April 2026 Category 2 withdrawal. The NC Board of Pharmacy does not have authority to add a bulk substance to that federal list. NC Board of Pharmacy rules incorporate federal compounding standards, as outlined under G.S. § 90-85.3 and the Board's administrative code.

The North Carolina Medical Practice Act

Physicians licensed in North Carolina operate under the NC Medical Practice Act (G.S. Chapter 90, Article 1). A physician may, within the limits of their professional judgment, prescribe an unapproved substance for off-label or investigational use under certain conditions, including IRB oversight for investigational drugs. The FDA's rules on investigational use of unapproved drugs, found at 21 CFR Part 312, require an active Investigational New Drug (IND) application for most human administration of unapproved drug substances. Prescribing BPC-157 to patients outside of an IND framework is legally problematic even for licensed NC physicians.

Possession and Personal Use

Possession of BPC-157 by an individual in North Carolina, absent intent to distribute, is not clearly criminalized under state law. The more significant risk comes from the federal angle: purchasing BPC-157 from an online vendor who misrepresents it as a supplement, or who ships it across state lines without proper drug establishment registration, may violate federal misbranding and adulteration statutes even if the buyer believes they are doing nothing wrong.

How People Currently Try to Access BPC-157 in North Carolina

Despite the regulatory barriers, BPC-157 continues to circulate. Understanding the access routes helps patients and clinicians assess real-world risk.

Route 1: Research Chemical Vendors

Numerous online vendors sell BPC-157 labeled "for research use only, not for human use." These vials are often lyophilized (freeze-dried) powder intended for laboratory reconstitution. Purchasing from these vendors for personal injection is not sanctioned by any regulatory body. The product quality, sterility, and actual peptide content are unverified. Because no FDA-registered manufacturer produced them for human use, they lack certificate-of-analysis verification that meets pharmaceutical standards.

Route 2: Telehealth Clinics Claiming to Prescribe It

Some telehealth platforms claim to prescribe BPC-157 through compounding pharmacies. Given that BPC-157 still is not on the 503A or 503B bulks lists, any compounding pharmacy filling such a prescription would be operating outside the 503A/503B frameworks. Patients using this route should understand that the legal status of both the prescribing physician and the dispensing pharmacy is, at minimum, contested. The FDA has taken enforcement action against compounding pharmacies that compound substances on the Category 2 list, as documented in multiple Warning Letters published on the FDA's website.

Route 3: Participation in a Clinical Trial

The only legally clean route to human BPC-157 administration in the United States is enrollment in an approved clinical trial with an active IND. A search of ClinicalTrials.gov as of July 2025 shows no actively recruiting Phase 2 or Phase 3 human trials for BPC-157 in the United States. Earlier-phase or pilot studies have been conducted in Croatia, where PL-10 (the branded formulation of BPC-157) has been studied in small cohorts for inflammatory bowel disease, but those results have not been replicated in large, adequately powered trials.

Below is the HealthRX.com Legal Access Framework for BPC-157 in North Carolina, developed by our medical and regulatory team to help patients understand their options clearly:

HealthRX.com BPC-157 Legal Access Framework (North Carolina)

What the Clinical Evidence Actually Shows

The legal gray area might be worth navigating if the evidence for BPC-157 were strong. Here is what the published literature actually contains.

Animal and In-Vitro Data

The preponderance of published BPC-157 research is in rodent models. A 2018 review published in the Journal of Physiology-Paris summarized animal studies showing BPC-157 accelerated tendon-to-bone healing and reduced inflammation in rat models, but the authors explicitly cautioned that human translation remained unestablished. Rodent pharmacokinetics often differ substantially from human pharmacokinetics, particularly for peptides, which are subject to rapid proteolytic degradation in the human GI tract and variable bioavailability by injection route.

Human Data

Published human data on BPC-157 are limited to small case series and early-phase trials conducted primarily in Eastern Europe. No Phase 3 randomized controlled trial with a prespecified primary endpoint, adequate power, and peer-reviewed publication exists in the English-language literature as of mid-2025. The absence of this evidence is precisely why the FDA's PCAC could not place BPC-157 on the positive 503A list.

Dose and Safety Profile Unknowns

No validated human dose has been established. Studies in rodents have used doses ranging from 1 microgram per kilogram to 10 micrograms per kilogram by injection. Because BPC-157 has not completed FDA Phase 1 dose-escalation trials in humans, a maximum tolerated dose, a therapeutic dose range, and a comprehensive adverse effect profile in humans are all unknown. Patients using vendor-supplied BPC-157 are self-experimenting at unstudied doses with an unverified product.

What a North Carolina Prescriber Can Legitimately Tell You

A board-certified physician in North Carolina can discuss BPC-157 with a patient. Discussing evidence is not the same as prescribing a legal pharmaceutical. The American Academy of Family Physicians' guidance on off-label prescribing distinguishes between off-label use of FDA-approved drugs and administration of substances that have never received FDA approval at any stage. BPC-157 falls into the second category. A physician who writes a prescription for BPC-157 knowing it will be filled by a compounding pharmacy operating outside federal guidelines accepts meaningful professional and legal risk.

Comparing BPC-157 to Other Peptides in the Legal Field

Not all peptides share the same regulatory fate. Understanding where BPC-157 sits relative to other commonly requested peptides helps clarify the picture.

Peptides Currently on the FDA 503A Positive List

Several peptides have completed the FDA review process and appear on positive compounding lists. Oxytocin, for example, is a component of an FDA-approved drug and may be compounded under specific conditions. Sermorelin, a growth hormone-releasing hormone analog, has had prior FDA approval and a more established compounding history. The FDA's current 503A bulk substances list, updated regularly, includes substances with defined safety profiles and clinical utility.

Peptides in the Same Gray Zone as BPC-157

Thymosin Beta-4 (TB-500) and Epitalon were nominated for the 503A list and were also flagged on the Category 2 list; like BPC-157, both nominations were withdrawn in April 2026, and neither peptide has been added to the 503A bulks list. In July 2026 the FDA's PCAC also voted to recommend adding TB-500 and Epitalon to that list, but those votes remain advisory only. Patients sometimes group all research peptides together as if they share a single legal status. They do not. Each has been evaluated separately, and the FDA's conclusions differ.

Practical Guidance for North Carolina Patients Considering BPC-157

Given the current regulatory field, here is what a reasonable, well-informed approach looks like.

Step 1: Ask Your Provider Directly About Legal Status

Before spending money on any source, ask a licensed North Carolina prescriber whether they can legally prescribe BPC-157 through a pharmacy that is compliant with FDA compounding rules. If they cannot name the specific pharmacy and explain its legal basis for compounding BPC-157, that is a meaningful warning sign.

Step 2: Check the FDA Warning Letter Database

The FDA publishes warning letters issued to compounding pharmacies on its website. Before using any compounding pharmacy for peptide therapy, search its name in this database. A pharmacy that has received a warning letter for compounding Category 2 substances is operating under increased scrutiny.

Step 3: Consider Alternatives With Stronger Legal Standing

If your clinical goal is wound healing, anti-inflammatory support, or gut mucosal protection, ask your prescriber about alternatives that carry FDA approval or a more established evidence base. For musculoskeletal inflammation, for example, biologics such as platelet-rich plasma (used in clinical practice under a different regulatory pathway) or NSAIDs with decades of safety data may address your symptoms within a fully legal framework.

Step 4: Monitor the ClinicalTrials.gov Registry

The National Institutes of Health ClinicalTrials.gov registry lists all FDA-authorized human trials. If a properly designed Phase 2 or Phase 3 trial for BPC-157 opens enrollment in the United States, that becomes the only legally clean route to access this peptide under a qualified medical team. Check the registry periodically if you remain interested.

Summary of Key Points

BPC-157 is not a DEA-controlled substance in North Carolina. State law does not explicitly prohibit possession. The practical barriers are entirely federal: BPC-157 is not on the FDA's 503A bulks list, and the April 2026 withdrawal of its Category 2 nomination did not change that, so licensed 503A and 503B compounding facilities still are not supposed to compound it for human use. No Phase 3 human trial has established safety or efficacy. Research chemical vendors selling it for "research use only" are not a compliant source for human injection. The only fully lawful route to human administration is an active IND or clinical trial, and no such trial is currently recruiting in the United States.

A licensed North Carolina physician can discuss BPC-157 with you. They cannot write a legally clean prescription for injectable BPC-157 at a compliant compounding pharmacy given the current FDA framework. Patients who proceed through gray-area channels do so outside the boundaries of what federal law and FDA guidance sanction, and they assume the product-quality and safety risks that come with an unstudied, unverified substance.